The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
News|Articles|November 27, 2018
Catalent Expands Clinical Packaging Capabilities in Shanghai, China
Author(s)Pharmaceutical Technology Editors
Catalent will expand primary packaging capabilities and commission an automated, high-speed bottling line for clinical packaging of capsules and tablets.
Advertisement
Catalent Pharma Solutions announced in a Nov. 27, 2018 press release that work to expand its primary packaging capabilities at its clinical facility in Shanghai, China has reached the commissioning stage and is scheduled to be completed by the end of 2018.
The expansion includes a new automated, high-speed bottling line suitable for capsule and tablet products. The line will increase packaging capacity by up to 100 bottles per minute and provide for quick and easy changeover, which is essential for clinical-scale production.
“Our continued investment in Asia Pacific reflects the importance of, and the continued growth of clinical trials in Asia, driving the need for in-region packaging services,” said Roel de Nobel, Catalent’s vice-president, Global Operations, Clinical Supply Services, in the press release.
This expansion follows the announcement that work is underway to open a new clinical facility outside of Shanghai’s free trade zone (FTZ). The new facility is expected to be completed in early 2019 and will join the company’s existing three clinical packaging facilities in the Asia Pacific region, namely in Shanghai’s Waigaoqiao FTZ; Singapore; and Kakegawa, Japan. In addition to its primary packaging capabilities, the company offers comprehensive clinical supply solutions in the region including clinical supply management, comparator sourcing, FastChain demand-led supply, secondary packaging, storage and global distribution, and clinical returns and destruction.
Source:
Advertisement
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
Advertisement
Advertisement